Wilmington PharmaTech targets larger commercial API volumes with $50m Delaware expansion
Wilmington PharmaTech is investing $50 million to expand Delaware API capacity. Read why this could reshape U.S. small-molecule supply.
Pharma & Biotech
Pharma & Biotech
WuXi Biologics to support Vertex’s autoimmune TCE R&D with full CRDMO integration
Vertex licenses trispecific TCE from WuXi Biologics for autoimmune drug R&D. Explore platform risks, modality fit, and strategic expansion in this analysis.
Pharma & Biotech
Frontage expands US–China clinical footprint to meet demand for early phase integration
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.